LSE - Delayed Quote GBp
Awakn Life Sciences Corp. (SVNS.L)
0.1325
0.0000
(0.00%)
At close: May 30 at 4:19:12 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
5/31/2021
Total Revenue
207
587
542
520
Cost of Revenue
35
329
242
30
Gross Profit
172
258
300
490
Operating Expense
2,186
2,468
2,991
932
Operating Income
-2,014
-2,210
-2,691
-442
Net Non Operating Interest Income Expense
-64
-3
-4
-7
Pretax Income
-2,790
-3,120
-2,705
-451
Tax Provision
0
0
0
0
Net Income Common Stockholders
-2,947
-3,120
-2,705
-451
Diluted NI Available to Com Stockholders
-2,947
-3,120
-2,705
-451
Basic EPS
-0.02
-0.03
-0.03
-0.00
Diluted EPS
-0.02
-0.03
-0.03
-0.00
Basic Average Shares
606,654.9800
104,057.2990
103,589.4790
104,097.2990
Diluted Average Shares
2,295,930.6330
104,057.2990
103,589.4790
104,097.2990
Total Operating Income as Reported
-2,858
-3,117
-2,701
-444
Total Expenses
2,221
2,797
3,233
962
Net Income from Continuing & Discontinued Operation
-2,947
-3,120
-2,705
-451
Normalized Income
-2,091
-2,282
-2,705
-451
Interest Expense
64
3
4
7
Net Interest Income
-64
-3
-4
-7
EBIT
-2,726
-3,117
-2,701
-444
EBITDA
-2,679
-2,938
-2,588
-335
Reconciled Cost of Revenue
35
329
242
30
Reconciled Depreciation
46
177
113
109
Net Income from Continuing Operation Net Minority Interest
-2,790
-3,120
-2,705
-451
Total Unusual Items Excluding Goodwill
-699
-838
0
--
Total Unusual Items
-699
-838
0
--
Normalized EBITDA
-1,980
-2,100
-2,588
-335
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
5/31/2021 - 1/6/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade